Rosalind Kalb from the National Multiple Sclerosis Society: Treating Advanced Disease in Multiple Sclerosis

Video

Defining what advanced disease means in multiple sclerosis is a topic open for discussion. Deciding a course of treatment after that determination is another challenge in overall patient care.

Defining what advanced disease means in multiple sclerosis is a topic open for discussion. Deciding a course of treatment after that determination is another challenge in overall patient care.

Rosalind Kalb, PhD, from the National Multiple Sclerosis Society discussed this issue during the annual meeeting of the Consortium of Multiple Sclerosis Centers in National Harbor, Maryland. Kalb said that while there may be disagreement on what qualifies as advanced disease there is no question that patients in this classification need a specialized level of care through the later stages of their disease.

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.